NONAPEPTIDE-1

Skin, Hair & CosmeticCosmetic

Limited but encouraging evidence with only one human trial, though the mechanistic research is solid. The peptide shows promise but needs more robust clinical testing to establish its real-world effectiveness.

Primarily investigated by cosmetic chemists developing depigmentation products and dermatology researchers studying melasma treatments.

FDA Status

Research Only

Since Feb 2026

Evidence

Moderate

Studies

4 total, 1 human

What is NONAPEPTIDE-1?

Also marketed under the name Melanostatine, this nine-amino-acid synthetic peptide has carved out a niche in cosmetic formulations targeting hyperpigmentation and uneven skin tone. The peptide works by interfering with the cellular machinery that produces melanin, making it a sought-after ingredient in skin brightening products. Dermatology researchers and cosmetic scientists study it primarily for conditions like melasma and age spots.

The peptide essentially acts as a molecular imposter, mimicking alpha-MSH (a hormone that triggers melanin production) but binding to MC1R receptors without activating them. Think of it like jamming a lock with the wrong key—it fits but doesn't turn, preventing the real key from working. This blocks the cascade of cellular events that normally leads to melanin synthesis, including the activation of tyrosinase, the enzyme responsible for the first steps in pigment production.

What the Research Shows

Research portfolio is thin with just 4 studies total, including only a single human trial that tested a combination formula rather than the peptide alone.

One randomized controlled trial demonstrated that a proprietary combination containing NONAPEPTIDE-1 was efficacious versus sunscreen in melasma maintenance. Supporting mechanistic studies (3 total) in human and cellular models showed that formulations with NONAPEPTIDE-1 and tea polyphenols inhibited UVA-induced melanogenesis through the α-MSH-MC1R pathway and enhanced skin benefits through nanoparticle delivery systems.